Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AMPH - Amphastar Pharmaceuticals Inc


IEX Last Trade
48.75
-0.110   -0.226%

Share volume: 205,062
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.87%

PREVIOUS CLOSE
CHG
CHG%

$48.86
-0.11
-0.23%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
48%
Profitability 60%
Dept financing 32%
Liquidity 75%
Performance 32%
Company vs Stock growth
vs
Performance
5 Days
1.65%
1 Month
11.99%
3 Months
15.63%
6 Months
-10.96%
1 Year
-10.34%
2 Year
62.25%
Key data
Stock price
$48.75
P/E Ratio 
14.25
DAY RANGE
$48.25 - N/A
EPS 
$3.14
52 WEEK RANGE
$36.56 - $65.92
52 WEEK CHANGE
-$0.11
MARKET CAP 
2.372 B
YIELD 
N/A
SHARES OUTSTANDING 
48.676 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
0.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$279,908
AVERAGE 30 VOLUME 
$382,218
Company detail
CEO: Jack Zhang
Region: US
Website: http://www.amphastar.com
Employees: 312
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int

Recent news